Alvotech to present switching study data for avt02, a proposed biosimilar to humira®, at 2022 american college of rheumatology conference

Reykjavik, iceland, nov. 10, 2022 (globe newswire) -- alvotech (nasdaq: alvo), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that it will present two posters and will be featured in an ignite talk related to its switching study for atv02 at the american college of rheumatology (acr) convergence conference, being held in philadelphia on november 10-14, 2022.
ALVO Ratings Summary
ALVO Quant Ranking